RU2013113188A - Комбинированное лечение дерматологических состояний - Google Patents

Комбинированное лечение дерматологических состояний Download PDF

Info

Publication number
RU2013113188A
RU2013113188A RU2013113188/15A RU2013113188A RU2013113188A RU 2013113188 A RU2013113188 A RU 2013113188A RU 2013113188/15 A RU2013113188/15 A RU 2013113188/15A RU 2013113188 A RU2013113188 A RU 2013113188A RU 2013113188 A RU2013113188 A RU 2013113188A
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
acceptable salt
brimonidine
oxymetazoline
composition
Prior art date
Application number
RU2013113188/15A
Other languages
English (en)
Russian (ru)
Inventor
Михаэль Грэбер
Мэтью Джеймс ЛЕОНИ
Натали ВАГНЕР
Original Assignee
Галдерма С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Галдерма С.А. filed Critical Галдерма С.А.
Publication of RU2013113188A publication Critical patent/RU2013113188A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41681,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
RU2013113188/15A 2010-09-28 2011-09-27 Комбинированное лечение дерматологических состояний RU2013113188A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38726810P 2010-09-28 2010-09-28
US61/387,268 2010-09-28
US13/232,139 US20120076738A1 (en) 2010-09-28 2011-09-14 Combination treatment for dermatological conditions
US13/232,139 2011-09-14
PCT/US2011/053455 WO2012050831A2 (en) 2010-09-28 2011-09-27 Combination treatment for dermatological conditions

Publications (1)

Publication Number Publication Date
RU2013113188A true RU2013113188A (ru) 2014-11-10

Family

ID=45870879

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013113188/15A RU2013113188A (ru) 2010-09-28 2011-09-27 Комбинированное лечение дерматологических состояний

Country Status (10)

Country Link
US (3) US20120076738A1 (enExample)
EP (1) EP2621498A4 (enExample)
JP (1) JP2013542930A (enExample)
KR (1) KR20140056129A (enExample)
CN (1) CN103354744A (enExample)
AU (1) AU2011314151A1 (enExample)
CA (1) CA2821993A1 (enExample)
MX (1) MX2013003639A (enExample)
RU (1) RU2013113188A (enExample)
WO (1) WO2012050831A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130079312A1 (en) * 2011-09-28 2013-03-28 Elorac, Ltd. Method of Treating Hair Loss Due to Systemic Chemotherapy
MX373977B (es) * 2013-05-06 2020-07-13 Allergan Inc Agonistas alfa adrenergicos para el tratamiento de traumatismo de tejidos.
US20150258011A1 (en) * 2014-03-15 2015-09-17 Marty Richard Hunter Treatment of keratinized tissues
JP2018506570A (ja) * 2015-02-24 2018-03-08 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ ドライアイ疾患及び他の眼障害の治療のための方法及び組成物
EP3319607A4 (en) 2015-07-09 2019-04-03 Galderma S.A. METHOD FOR REDUCING HAIR LOSS IN CONNECTION WITH CHEMOTHERAPY
RU2605687C1 (ru) * 2015-09-21 2016-12-27 Ирина Николаевна Усманова Способ лечения рецидивирующего афтозного стоматита
EP3624773A4 (en) 2017-05-19 2021-04-07 Ocugen, Inc. OPHTHALMIC COMPOSITIONS AND METHOD OF USE
US20190321416A1 (en) * 2018-04-18 2019-10-24 Forte Biosciences, Inc. Compositions for the treatment of skin conditions
US20210188817A1 (en) * 2018-08-29 2021-06-24 Cellix Bio Private Limited Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases
WO2020065085A1 (fr) * 2018-09-28 2020-04-02 Galderma Research & Development Composition pharmaceutique comprenant de la brimonidine, et ses utilisations
US20220096467A1 (en) * 2019-01-12 2022-03-31 Cellix Bio Provate Limited Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof
WO2020222192A1 (en) * 2019-05-01 2020-11-05 Clexio Biosciences Ltd. Methods of treating pruritus
CA3137267A1 (en) 2019-05-01 2020-11-05 Clexio Biosciences Ltd. Methods of treating pruritus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
CN104490884A (zh) * 2004-05-25 2015-04-08 桑斯罗萨医药发展公司 治疗或预防炎症性皮肤疾病的化合物、制剂及方法
SI2182960T1 (sl) * 2007-07-27 2014-07-31 Galderma Laboratories Inc. Spojine, formulacije in postopki za zmanjĺ anje koĺ˝nih gub, meäśkanja in poveĺ anja
EP2818184B1 (en) * 2007-11-16 2018-10-31 Allergan, Inc. Compositions and methods for treating Purpura
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
CA2810746A1 (en) * 2010-06-30 2012-01-05 Galderma Research & Development Method for preventing or treating skin tumor
US20120082625A1 (en) * 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
RU2014119879A (ru) * 2011-10-19 2015-11-27 Галдерма С.А. Способ снижения прилива крови к лицу при систематическом использовании ингибиторов фосфодиэстеразы типа 5

Also Published As

Publication number Publication date
JP2013542930A (ja) 2013-11-28
WO2012050831A2 (en) 2012-04-19
AU2011314151A1 (en) 2013-04-11
KR20140056129A (ko) 2014-05-09
US20150313895A1 (en) 2015-11-05
WO2012050831A3 (en) 2012-06-14
MX2013003639A (es) 2013-09-16
US20120076738A1 (en) 2012-03-29
EP2621498A2 (en) 2013-08-07
CN103354744A (zh) 2013-10-16
US20140094470A1 (en) 2014-04-03
CA2821993A1 (en) 2012-04-19
EP2621498A4 (en) 2014-04-09

Similar Documents

Publication Publication Date Title
RU2013113188A (ru) Комбинированное лечение дерматологических состояний
JP2013542930A5 (enExample)
WO2012075319A3 (en) Pharmaceutical cream compositions comprising oxymetazoline
AU2010313643B2 (en) Methods of treating or preventing acute erythema
EA201890218A1 (ru) Ретиноидные композиции для местного применения
UA117573C2 (uk) Біциклічні сполуки сечовини, тіосечовини, гуанідину й ціаногуанідину, придатні для лікування болю
MX392440B (es) Inhibidores de tirosina quinasa de bazo (syk).
JP2013538853A5 (enExample)
AR060631A1 (es) Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
EP2887928B1 (en) Retinoids and use thereof
AR092860A1 (es) Formulacion oftalmica y metodo para mejorar la presbicia
RU2012124904A (ru) КОМБИНАЦИЯ АГОНИСТА α2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ И НЕСТЕРОИДНОГО ПРОТИВОВОСПАЛИТЕЛЬНОГО СРЕДСТВА ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ВОСПАЛИТЕЛЬНОГО ПОРАЖЕНИЯ КОЖИ
RU2014150505A (ru) Способ идентификации лигандов рецептора ahr, которые обладают терапевтической себосупрессивной активностью, и указанные лиганды
AR065317A1 (es) Uso de quitosanos, derivados de quitosanos y una sal fisiologicamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales
MX2014014818A (es) Composicion farmaceutica para el tratamiento de enfermedades inflamatorias de la piel.
WO2013103924A3 (en) Liposomally encapsulated reduced glutathione for management of cancer, including with other pharmaceutical compositions
RU2014129514A (ru) [1,2,4]триазолопиридины и их применение в качестве ингибиторов фосфодиэстеразы
WO2013182998A4 (en) Cosmetic and / or pharmaceutical composition for the treatment of skin inflammation and related syndromes
US11224618B2 (en) Formulations and methods for treatment of acne and inflammatory skin conditions
BR112015027569A2 (pt) compostos, composições, métodos e respectivos usos para tratar doenças por meio da inibição da atividade de tgf-ß
RU2014119919A (ru) Способ лечения капиллярных гемангиом
CL2024003959A1 (es) Formulaciones tópicas de benzimidazol y métodos para su uso en el tratamiento de dermatosis inflamatorias.
AR094027A1 (es) Formulaciones topicas que contienen pidotimod
JP2014518265A (ja) レチノイド局所用組成物および皮膚疾病を治療するための方法
EP3164110B1 (en) Pharmaceutical compositions for the treatment of psoriasis

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20161027